HTL Biotechnology in the news
Biopolymer production market leader
Tamtam found 20 recent articles about HTL Biotechnology.
- HTL Biotechnology vise une commercialisation dès 2029 d’un nouveau collagène recombinant
HTL Biotechnology plans to commercialize a novel human recombinant collagen (rhCOL3) by 2029, targeting the regenerative and wound healing medicine market from its US base.
- Pour la première fois, cette entreprise historique d’Ille-et-Vilaine dévoile les coulisses de son site à des étudiants
HTL Biotechnology opened its Javené site to students to showcase bioproduction careers and innovations, with plans for a new polynucleotide production unit following 100 million euros in revenue for 2025.
- Pour la première fois, cette entreprise historique d’Ille-et-Vilaine dévoile les coulisses de son site à des étudiants
HTL Biotechnology hosted its first open house for students in Javené to showcase bioproduction careers and its upcoming manufacturing expansion for skin regeneration components.
- Pour la première fois, cette entreprise historique d’Ille-et-Vilaine dévoile les coulisses de son site à des étudiants
HTL Biotechnology opened its Javené site to students for the first time to introduce them to the bioproduction industry and its innovations, with plans for further expansion.
- HTL sets eyes on Korea to drive Asia growth
HTL Biotechnology is expanding in South Korea to drive Asia growth by partnering with local firms in regenerative medicine and advancing biopolymer technologies.
- HTL sets eyes on Korea to drive Asia growth
HTL Biotechnology is focusing on South Korea to expand its Asia presence by partnering on advanced biopolymer and regenerative medicine developments.
- We will grow Korea not just as a market for selling products, but as a key base for designing the f..
HTL Biotechnology is focusing on Korea as a key base for advancing biopolymer development and regenerative medicine through strong local partnerships and innovative technologies.
- Hyaluronic Acid Raw Material Market Size to Hit USD 12.33 Billion by 2035
The hyaluronic acid raw material market is projected to reach USD 12.33 billion by 2035, driven by increasing demand from the cosmetics and pharmaceutical industries.
- Hyaluronic Acid API Market Overview
The hyaluronic acid API market is experiencing rapid growth, driven by demand in cosmetic and medical sectors and a shift towards microbial fermentation production methods.
- Biotechnologies. Pourquoi HTL Biotechnology investit 12 M€ dans l’acide hyaluronique stérile
HTL Biotechnology invests €12 million to boost sterile hyaluronic acid production, targeting medical aesthetics and ophthalmology sectors.
- Ille-et-Vilaine : l'entreprise HTL va produire de l'acide hyaluronique stérile
HTL Biotechnology is launching a new sterile hyaluronic acid production unit in France, investing heavily to serve pharmaceutical clients in ophthalmology and regenerative medicine starting in 2026.
- Ophtalmologie, rhumatologie : HTL Biotechnology investit pour de nouveaux traitements
HTL Biotechnology invested €12 million in a new sterile hyaluronic acid production unit to enable innovative ophthalmology and rheumatology treatments.
- HTL Biotechnology inaugure une unité de…
HTL Biotechnology is expanding its pharmaceutical-grade sterile hyaluronic acid and DNA production with new facilities and investments, targeting therapeutic markets and international growth by 2026.
- HTL Biotechnology inaugure une unité de production d’acide hyaluronique stérile unique en Europe
HTL Biotechnology is expanding with a unique sterile hyaluronic acid production unit and increased DNA production capacity, targeting therapeutic markets and international growth by 2026.
- HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
HTL Biotechnology launched a new sterile hyaluronic acid production line in France to enable advanced therapeutic formulations and strengthen its biopolymer leadership.
- HTL Biotechnology inaugure une nouvelle ligne de production dédiée à l'acide hyaluronique stérile
HTL Biotechnology has opened a new sterile hyaluronic acid production line in France, enabling advanced therapeutic applications and reinforcing its leadership in pharmaceutical-grade biopolymers.
- 12 M€ pour la production d’acide hyaluronique : HTL Biotechnology se renforce en Ille-et-Vilaine
HTL Biotechnology is expanding its Javené facility with a €12 million sterile hyaluronic acid production line, aiming to start production in 2026 and diversify its product portfolio.
- En Ille-et-Vilaine, l’entreprise HTL dévoile une unité de production presque unique au monde
HTL expanded its Fougères site with a new unit producing sterile, pharmaceutical-grade hyaluronic acid powder.
- La biotech HTL injecte 100 millions d’euros dans son centre breton
Biotech leader HTL plans a 100 million euro investment to expand its pharmaceutical-grade biopolymer production and R&D facilities in Javené.
- Modern Meadow Sells its Beauty and Biomedical Divisions to HTL Biotechnology
Modern Meadow divests its beauty and biomedical units to HTL Biotechnology to concentrate on sustainable biomaterials innovation.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like HTL Biotechnology?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies